계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Abliva AB
company
About
Abliva develops medicines for the treatment of primary mitochondrial diseases.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $4.09M
- Industries
- Biotechnology,Clinical Trials,Health Care
- Founded date
- Jan 1, 2000
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$4.09M
Abliva AB has raised a total of
$4.09M
in funding over 2 rounds. Their latest funding was raised on
Aug 29, 2018 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 29, 2018 | Grant | $4.09M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Abliva AB is funded by 1 investors.
Congressionally Directed Medical Research Programs
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
